ArticleCurrent oncology (Toronto, Ont.)2008
A primer of bone metastases management in breast cancer patients.
Article in Current oncology (Toronto, Ont.), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.
- Acupuncture for cancer pain in adults.The Cochrane database of systematic reviews · 2015Pooled it
- Histomorphometric and microarchitectural analysis of bone in metastatic breast cancer patients.Bone reports · 2021Article
- Combinatorial targeting of cancer bone metastasis using mRNA engineered stem cells.EBioMedicine · 2019Article
- Effect of bisphosphonate treatment on the jawbone: an exploratory study using periapical and panoramic radiographic evaluation.Oral radiology · 2019Article
- Malignancy-Related Hypercalcemia in Advanced Solid Tumors: Survival Outcomes.Journal of global oncology · 2017Article
- Targeted drug delivery of near IR fluorescent doxorubicin-conjugated poly(ethylene glycol) bisphosphonate nanoparticles for diagnosis and therapy of primary and metastatic bone cancer in a mouse model.Journal of nanobiotechnology · 2016Article
- Concurrent dendritic cell vaccine and strontium-89 radiation therapy in the management of multiple bone metastases.Irish journal of medical science · 2015Article
- Mandibular inferior cortical bone thickness on panoramic radiographs in patients using bisphosphonates.Oral surgery, oral medicine, oral pathology and oral radiology · 2015Article
- A modified method for reducing renal injury in zoledronic Acid treatment of hypercalcemia and adverse skeletal events.Indian journal of palliative care · 2013Article
- Fractal dimension evaluation of cone beam computed tomography in patients with bisphosphonate-associated osteonecrosis.Dento maxillo facial radiology · 2011Article
- Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies.Cancer management and research · 2011Article
- Article
- Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone is the most common site for distant spread of breast cancer. Following a diagnosis of metastatic bone disease, patients can suffer from significant morbidity because of pain and skeletal related events (SRES). Bisphosphonates are potent inhibitors of osteoclastic function and the mainstay of bone-directed therapy for bone metastases. The aims of bisphosphonates are to prevent and delay SRES, to reduce bone pain, and to improve quality of life. Bisphosphonate therapy appears to have revolutionized treatment of bone metastases, but bisphosphonate use has several limitations. Those limitations include the high cost of the agents and the need for return trips to the clinic for intravenous treatment. Moreover, many uncertainties surround bisphosphonate use-for example, the timing of bisphosphonate initiation, the choice of bisphosphonate to use, the optimal duration of treatment, and the appropriate means to identify patients who will and will not benefit. In addition, potentially serious adverse effects have been associated with bisphosphonate use-for example, renal toxicity, gastrointestinal side effects, and osteonecrosis of the jaw. The present review is intended as a primer for oncology specialists who treat patients with bone metastases secondary to breast cancer. It focuses on bisphosphonate treatment guidelines, the evidence for those guidelines, and a discussion of new therapeutic agents. It also discusses the use of biochemical markers of bone metabolism, which show promise for predicting the risk of a patient's developing a SRE and of benefiting from bisphosphonate treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.